This medication is teratogenic and is not currently approved for use in the treatment of Cushing's syndrome. [51] ACTH: Adrenocorticotrophic hormone; b.i.d.: Twice daily; GI: Gastrointestinal ...

Corcept Therapeutics Incorporated CORT recently announced the submission of a new drug application (NDA) to the FDA for its ...

Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the body ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Korlym became the first drug approved by the FDA to treat Cushing syndrome in 2012. It wasn’t until recently, however, that researchers discovered that hypercortisolism, previously believed to ...

radiotherapy or drug therapy. While medical therapy for Cushing's syndrome has been limited, several new agents are being investigated. This aim of this review is to analyze and present the ...

CORT’s sole marketed drug, Korlym (mifepristone), is already approved for treating Cushing's syndrome. The drug has been witnessing a strong demand in the past couple of quarters and the trend ...

Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the ...